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Abstract
Background: Fluorescence in situ hybridization (FISH) is one of the most powerful genetic analysis tools for
pathological diagnoses. FISH can detect various genetic abnormalities including gene translocation that was
specifically found in translocation-related sarcomas (TRSs). Here, we report the use of FISH in expert review in a
phase 2 study of trabectedin monotherapy for patients with advanced TRS.
Methods: TRS patients (n = 76) were enrolled in the trial at 12 study sites after pathological diagnoses were made,
including morphological examination with or without evidence of translocation by genetic testing. Following
histological reviews of the representative specimens at the study sites, we performed immunohistochemistry
using the appropriate antibodies and FISH for genetic confirmation of the tumor types in the expert review.
Results: Among the 76 TRS cases, no split signal for SS18 probe was detected by FISH in three synovial sarcoma
cases that were diagnosed at the study sites. Malignant peripheral nerve sheath tumor (MPNST) was diagnosed in
two cases and sarcomatoid carcinoma in one. One of the cases was a small round cell variant of MPNST. After
excluding these three cases, we assessed the other 73. There were no split signals detected in 7 of the 73 cases by
FISH analysis, due to decalcification and hyperfixation procedures. Excluding these seven cases, FISH detected
translocations in 95 % (63/66) of the study cases with a high sensitivity.
Conclusions: The diagnosis of TRS by FISH was highly sensitive and enabled genetic confirmation of the
pathological diagnoses. We strongly recommend FISH as a confirmatory diagnostic test for TRS, which would
enable the selection of patients with TRS in whom trabectedin is expected to be effective.
This study was done in part that registered with Japan Pharmaceutical Information Center, number JapicCTI-121850.
Keywords: Fluorescence in situ hybridization, Translocation-related sarcoma, Immunohistochemistry, Synovial
sarcoma, Malignant peripheral nerve sheath tumor, Sarcomatoid carcinoma
Background
In general, sarcomas can be divided into two groups
that comprise translocation-related sarcomas (TRSs)
and non-TRSs [1]. The TRS group has a specific
chimeric gene derived from a chromosome transloca-
tion inherent in specific tumor types. Fluorescence in
situ hybridization (FISH) is one of the most powerful
genetic research tools for making a pathological diag-
nosis [2]. FISH using routine slide glass specimens
can detect various genetic abnormalities including
gene translocation that gives rise to some chimeric
genes, so it is suitable for genetic confirmation of
TRSs.
Recently, Kawai et al reported the efficacy of trabectedin
monotherapy after chemotherapy versus best supportive
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care in patients with advanced TRS [3]. Trabectedin is a
tetrahydroisoquinoline alkaloid that has anti-tumor activ-
ities in soft tissue sarcomas and binds to the minor groove
of DNA and blocks DNA repair machinery [4]. Preclinical
data have shown that trabectedin also modulates the tran-
scription of the oncogenic fusion proteins of TRS and
some retrospective clinical studies have revealed that it is
effective in TRS patients [5–7]. The trial was performed as
a randomized, open-labeled, phase 2 study and demon-
strated that trabectedin significantly reduced the risk of
disease progression and death in patients with advanced
TRS after standard chemotherapy. Trabectedin was re-
cently approved in Japan after taking these results into
consideration. We took charge of the expert review of all
cases to confirm the primary pathological diagnosis ob-
tained from each study site. In addition to morpho-
logical examinations and immunohistochemistry (IHC),
we performed FISH, a practical and effective method,
to obtain genetic confirmation of TRS diagnosis. To
date, there are no detailed reports on the use of FISH
for the genetic analysis of TRS cases in clinical trials.
Here, we report the use of this method for genetic in-
vestigations in a clinical trial.
Methods
Case selection and relevant immunohistochemistry in
expert review
TRS patients (n = 76) were enrolled in a trial involving
12 study sites after pathological diagnoses had been
made, which were based on morphological examinations
with or without evidence of translocation on genetic
investigation. The 76 TRS patient were diagnosed as
follows: 24 myxoid liposarcomas (MLS), 21 synovial
sarcomas (SS), 6 mesenchymal chondrosarcomas (MCS),
5 extraskeletal Ewing sarcomas (EES), 5 alveolar soft
part sarcomas (ASPS), 5 alveolar rhabdomyosarcomas
(ARMS), 5 clear cell sarcomas (CCS), 2 extraskeletal
myxoid chondrosarcomas (EMC), 1 dermatofibrosar-
coma protuberans (DFSP), 1 angiomatoid fibrous his-
tiocytoma (AFH), and 1 desmoplastic small round cell
tumor (DSRCT). IHC had already been conducted at
each study site using appropriate antibodies for
pathological diagnosis before the expert review com-
menced. We reviewed the histology of the representa-
tive specimens at the study sites and performed IHC
with relevant antibodies in expert review to estimate
the diagnostic consistency at the study sites before
genetic confirmation of the tumor types by FISH. The
following antibodies were used to confirm the tumor
types in the expert review: vimentin (V9; Dako,
Carpinteria, CA), S-100 (polyclonal; Dako), MDM2
(Ab-1; Calbiochem, Darmstadt, Germany), and CDK4
(DCS-31; Invitrogen, Carlsbad, CA) for MLS; vimen-
tin, bcl-2 (Bcl2; Dako), cytokeratin (AE1/AE3; Dako),
epithelial membrane antigen (EMA) (E29; Dako), and
c-kit (c-kit; Dako) for SS; vimentin, MIC2 (CD99)
(12E7; Dako), S-100 for MCS; vimentin, MIC2, synapto-
physin (SY38; Dako), and neurofilament (2 F11; Dako) for
EES; TFE3 (polyclonal; Santa Cruz Biotechnology, Santa
Cruz, CA) and vimentin for ASPS; desmin (D33; Dako),
muscle-specific actin (HHF35; Dako), myogenin (F50;
Dako), and vimentin for ARMS; vimentin, S-100,
melanosome (HMB-45; Dako), and SOX-10 (poly-
clonal; Santa Cruz Biotechnology) for CCS; vimentin,
S-100, NSE (polyclonal; Dako), and synaptophysin
for EMC; CD34 (QBEnd10; Dako), vimentin for
DFSP; vimentin, desmin, CD68 (PG-M1; Nichirei,
Tokyo, Japan), MIC2, and EMA for AFH; and cyto-
keratin, EMA, desmin, and synaptophysin for
DSRCT. Both the study protocol and the informed
consent form were approved by the institutional re-
view board at each study site. All patients gave writ-
ten informed consent for enrollment into the clinical
trial and the expert review [3].
Fluorescence in situ hybridization
FISH was performed at SRL Medisearch Inc. (Tokyo,
Japan) according to our routine procedure, which uses
various commercial and in-house probes, as previously
described [2]. We used dual-colored, split-signal probe
sets for MLS, SS, EES, ASPS, ARMS, CCS, EMC, DFSP,
AFH, and DSRCT, and in-house dual-colored, fusion-
signal probe sets for MCS cases (Table 1). To estimate
the rate of split signals, “split” was defined when the dis-
tance between the orange and green signals was as least
twice that of the estimated signal diameter. We counted
50 nuclei and considered each case to be either positive,
negative, or indeterminate if the split signals were ob-
served in more than 25 (50 %) tumor cells, less than 2
(4 %) tumor cells, or 2 to 24 (4 to 48 %) tumor cells, re-
spectively. Second, 50 nuclei in indeterminate cases were
counted by another observer and the case was consid-
ered positive if the split signals were found in more than
5 (10 %) tumor cells. The rate of fusion signals was de-
fined when orange and green signals completely over-
lapped, producing a yellow signal. We first counted 100
nuclei and considered each case as positive, negative, or
indeterminate if the fusion signals were observed in
more than 50 tumor cells (50 %), less than 10 (10 %)
cells, and 10 to 49 (10 to 49 %) cells, respectively. In in-
determinate cases, 100 nuclei were counted by another
observer and the cases were considered positive if fusion
signals were found in more than 21 (21 %) tumor cells.
FISH signals were estimated on a Nikon ECLIPSE E600
microscope (NIKON CORPORATION, Tokyo, Japan)
at 100× magnification with oil immersion, using a
DAPI/green/orange filter set. The results of FISH
were confirmed by T.H.
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Results
The results of the confirmatory IHC tests in expert re-
view largely supported the findings of the pathological
diagnoses at the study sites, and there were no major
discrepancies between morphological examinations and
IHC results. We used FISH analysis to examine the 76
cases for genetic confirmation of pathological diagnoses
(Table 2). Among these cases, SS18 split signals were
not detected in three of the SS cases diagnosed at the
study sites. MPNSTs were diagnosed in two cases and
sarcomatoid carcinoma in one. The diagnosis of these
three cases by morphology and IHC alone was challen-
ging. One MPNST case showed solid proliferation of
small round tumor cells but did not have the fascicular
structure of spindle tumor cells, a typical MPNST fea-
ture (Fig. 1a). The tumor cells were diffusely positive for
vimentin, focally positive for S-100 (Fig. 1b) and bcl-2,
sparsely positive for cytokeratin (Fig. 1c), and negative
for EMA and c-kit. Additional IHC revealed diffuse
CD56 positivity. This case required differentiation from
poorly differentiated SS, although SS18 split signals were
not detected (Fig. 1d). The case was finally diagnosed as
a round cell-type MPNST.
Another MPNST case consisted of fascicular prolifera-
tion of spindle tumor cells and showed typical spindle
cell sarcoma features. IHC showed that these tumor cells
were diffusely positive for vimentin, focally positive for
cytokeratin and EMA, and negative for S-100, bcl-2, and
c-kit. Additional IHC showed diffuse CD56 positivity.
No SS18 split signals were observed and we finally diag-
nosed the case as ordinary MPNST.
In contrast, in the sarcomatoid carcinoma case, the
tumor consisted of sheet-like and glandular proliferation
of epithelioid tumor cells (Fig. 2a). The tumor cells were
diffusely positive for cytokeratin (Fig. 2b), EMA, and
vimentin, and negative for bcl-2 (Fig. 2c). The differen-
tial diagnosis in this case was epithelioid SS, but FISH
detected a polyploidy pattern without SS18 split signals
(Fig. 2d). We made a final diagnosis of sarcomatoid
carcinoma.
The results of IHC corresponded to the histological
diagnoses, although there was one SS case that demon-
strated an unusual IHC staining pattern and was difficult
to diagnose without FISH. The tumor consisted of solid
proliferations of epithelioid and round tumor cells
(Fig. 3a) and was similar to poorly differentiated SS, al-
though no reactivity to cytokeratin and EMA was de-
tected by IHC (Fig. 3b, c). FISH revealed SS18 split
signals in the tumor cells and the case was diagnosed as
SS (Fig. 3d). As mentioned above, the histological diag-
noses of the 10 tumor types except for SS made at the
study sites matched those of expert review.
We assessed the 73 TRS cases after excluding 3 cases.
No signals were detected by FISH analysis in 7 of the 73
TRS cases. These cases included 2 MLS cases, 3 MCS
cases, 1 SS case, and 1 EES case. One of the MLS cases
had no nuclei due to karyorrhexis, and no green and or-
ange signals were detected in 1 MLS case, 3 MCS cases,
1 SS case, and 1 EES case. These cases had undergone
decalcification because they contained bony tissue. One
EES was a minute biopsy specimen and showed formalin
hyperfixation. Thus, the 7 cases with no FISH signals
were inappropriate for FISH analysis. Excluding the 7
cases, FISH detected translocations in 95 % (63/66) of
the 73 study cases with high sensitivity. In 1 SS case,
SS18-SSX fusion was detected by RT-PCR, although no
split signals were revealed by FISH. Moreover, one
ARMS and one EMC case proved negative for FISH.
Thus, it is thought that there were other chimeric fu-
sions affecting these cases [2].
Discussion
Morphological examination is undoubtedly the most
fundamental and important procedure for pathological
diagnosis. However, challenging cases require additional
genetic investigations to confirm the diagnosis. In this
study, we had some challenging cases in which the dif-
ferential diagnosis needed to be made carefully. Two
MPNST cases correctly diagnosed in expert review ex-
hibited focal cytokeratin and EMA reactivity, confirming
that distinguishing between SS and MPNST is essential.
MPNST does not always express S-100 and occasionally
has aberrant expression of epithelial markers, similar to
Table 1 List of FISH probes used in the expert review
Histological type Probe
Myxoid liposarcoma DDIT3 Dual Color Break Apart Probe
(Abbott Molecular Inc., IL)
Synovial sarcoma SS18 Dual Color Break Apart Probe
(Abbott Molecular Inc.)
Mesenchymal chondrosarcoma HEY1-NCOA2 fusion probe
(Chromosome Science Lab Inc.,
Sapporo, Japan)
Extraskeletal Ewing sarcoma EWSR1 Dual Color Break Apart
Probe (Abbott Molecular Inc.)
Clear cell sarcoma
Angiomatoid fibrous histiocytoma
Desmoplastic small round cell
tumor
Alveolar soft part sarcoma TFE3 split probe (Chromosome
Science Lab Inc.)
Alveolar rhabdomyosarcoma FOXO1 Dual Color Break Apart
Probe (Abbott Molecular Inc.)
Extraskeletal myxoid
chondrosarcoma
NR4A3 split probe (Chromosome
Science Lab Inc.)
Dermatofibrosarcoma protuberans PDGFB split probe (Chromosome
Science Lab Inc.)
Angiomatoid fibrous histiocytoma FUS Dual Color Break Apart Probe
(Abbott Molecular Inc.)
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the present cases [8, 9]. Moreover, MPNSTs express
CD56; therefore, we suspected MPNST and confirmed
the diagnosis by FISH. One of them was a small round
cell variant MPNST that characteristically consists of
small round tumor cells [10, 11]. This histological vari-
ant needs to be distinguished from poorly differentiated
SS. Both tumors typically consist of solid proliferations
of small round tumor cells and aberrant expression of
epithelial markers, so care must be taken in reaching the
differential diagnosis. SS sometimes shows no reactivity
to epithelial markers, especially in monophasic and
poorly differentiated cases [12, 13]. SS cases negative for
Fig 1 Representative images of a malignant peripheral nerve sheath tumor mimicking a poorly differentiated synovial sarcoma. a: The tumor
consisted of solid proliferations of uniform, round tumor cells with round to oval nuclei. b: Tumor cells were focally positive for S-100 protein on
IHC. c: Tumor cells were sparsely positive for cytokeratin AE1/AE3 on IHC, d: FISH revealed no SS18 split signals
Table 2 Comparison of the pathological diagnosis of the study sites and expert review by FISH analysis
Histological type Study site Expert review FISH
Positive Negative ND
Myxoid liposarcoma 24 24 22 0 2
Synovial sarcoma 21 18 16 4a 1b
Mesenchymal chondrosarcoma 6 6 3 0 3
Extraskeletal Ewing sarcoma 5 5 4 0 1
Alveolar soft part sarcoma 5 5 5 0 0
Alveolar rhabdomyosarcoma 5 5 4 1 0
Clear cell sarcoma 5 5 5 0 0
Extraskeletal myxoid chondrosarcoma 2 2 1 1 0
Dermatofibrosarcoma protuberans 1 1 1 0 0
Angiomatoid fibrous histiocytoma 1 1 1 0 0
Desmoplastic small round cell tumor 1 1 1 0 0
Total 76 73 63 6 7
aFour FISH-negative cases of synovial sarcoma included 2 MPNSTs, 1 sarcomatoid carcinoma, and 1 synovial sarcoma with SS18-SSX fusion detected by RT-PCR
bOne FISH ND case with SS18-SSX fusion detected by RT-PCR
ND, not detected, MPNST malignant peripheral nerve sheath tumor
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Fig 3 Representative images of poorly differentiated synovial sarcoma without cytokeratin expression. a: The tumor consisted of solid and
fascicular proliferations of round to short-spindle tumor cells with round to oval nuclei. b: Tumor cells were negative for cytokeratin AE1/AE3 on
IHC. c: Tumor cells were negative for EMA on IHC. d: FISH analysis revealed a pair of split and fused orange and green signals showing a SS18 split
pattern (arrows)
Fig 2 Representative images of sarcomatoid carcinoma after synovial sarcoma was excluded. a: The tumor had a pseudoglandular structure and a
sheet-like proliferation of cuboidal tumor cells. b: Tumor cells were positive for cytokeratin AE1/AE3 on IHC. c: Tumor cells were negative for bcl-2
on IHC. Infiltrating lymphocytes alone were bcl-2 positive. d: FISH analysis revealed no SS18 split signals. Nuclei showed more than two pairs of
orange and green signals with a polyploidy pattern (arrows)
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epithelial markers must therefore be distinguished from
various tumor types, given that confirmation of the
diagnosis without detection of a specific rearrangement
is challenging. We believe that the detection of a gene
rearrangement by FISH could facilitate confirmation of
the diagnosis in such situations.
FISH did not detect any signals in seven cases. These
cases had undergone formalin hyperfixation and decalci-
fication. Thus, these procedures might influence the
condition of the specimens and prevent the detection of
FISH signals. Specifically, the decalcification process
markedly affects study results; our previous study dem-
onstrated the negative effect of decalcification. We stud-
ied the use of FISH to detect HEY1-NCOA2 fusion in
MCS cases; some cases of tumors originating in the
bone showed no signals on FISH after the decalcification
process [14]. In the present study, three MCS cases had
no signals after decalcification, although a diagnosis of
MCS was easily reached because of the characteristic
histological findings.
Conclusion
We performed FISH for genetic confirmation of patho-
logical diagnoses in expert review during a clinical trial.
FISH demonstrated a high sensitivity for TRS and its
value as a genetic testing tool for clinical trials. We
strongly recommend FISH as a confirmatory diagnostic
test for TRS, which would enable the selection of pa-
tients with TRS who are expected to be effectively
treated by trabectedin.
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